HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation.

Abstract
We studied the role of the mineralocorticoid receptor (MR) in the signaling that promotes atrial fibrosis. Left atrial myocardium of patients with atrial fibrillation (AF) exhibited 4-fold increased hydroxyproline content compared with patients in sinus rhythm. Expression of MR was similar, as was 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), which also increased. 11β-HSD2 converts cortisol to receptor-inactive metabolites allowing aldosterone occupancy of MR. 11β-HSD2 was up-regulated by arrhythmic pacing in cultured cardiomyocytes and in a mouse model of spontaneous AF (RacET). In cardiomyocytes, aldosterone induced connective tissue growth factor (CTGF) in the absence but not in the presence of cortisol. Hydroxyproline expression was increased in cardiac fibroblasts exposed to conditioned medium from aldosterone-treated cardiomyocytes but not from cardiomyocytes treated with both cortisol and aldosterone. Aldosterone increased connective tissue growth factor and hydroxyproline expression in cardiac fibroblasts, which were prevented by BR-4628, a dihydropyridine-derived selective MR antagonist, and by spironolactone. Aldosterone activated RhoA GTPase. Rho kinase inhibition by Y-27632 prevented CTGF and hydroxyproline, whereas the RhoA activator CN03 increased CTGF expression. Aldosterone and CTGF increased lysyl oxidase, and aldosterone enhanced miR-21 expression. MR antagonists reduced the aldosterone but not the CTGF effect. In conclusion, MR signaling promoted fibrotic remodeling. Increased expression of 11β-HSD2 during AF leads to up-regulation of collagen and pro-fibrotic mediators by aldosterone, specifically RhoA activity as well as CTGF, lysyl oxidase, and microRNA-21 expression. The MR antagonists BR-4628 and spironolactone prevent these alterations. MR inhibition may, therefore, represent a potential pharmacologic target for the prevention of fibrotic remodeling of the atrial myocardium.
AuthorsDaniel Lavall, Christian Selzer, Pia Schuster, Matthias Lenski, Oliver Adam, Hans-Joachim Schäfers, Michael Böhm, Ulrich Laufs
JournalThe Journal of biological chemistry (J Biol Chem) Vol. 289 Issue 10 Pg. 6656-6668 (Mar 07 2014) ISSN: 1083-351X [Electronic] United States
PMID24469458 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • MIRN21 microRNA, human
  • MicroRNAs
  • Mineralocorticoid Receptor Antagonists
  • Receptors, Mineralocorticoid
  • Connective Tissue Growth Factor
  • Spironolactone
  • 11-beta-Hydroxysteroid Dehydrogenase Type 1
Topics
  • 11-beta-Hydroxysteroid Dehydrogenase Type 1 (biosynthesis)
  • Animals
  • Atrial Fibrillation (pathology)
  • Connective Tissue Growth Factor (metabolism)
  • Disease Models, Animal
  • Female
  • Fibroblasts (metabolism, pathology)
  • Fibrosis
  • Heart Atria (drug effects, pathology)
  • Humans
  • Male
  • Mice
  • MicroRNAs (metabolism)
  • Middle Aged
  • Mineralocorticoid Receptor Antagonists (pharmacology)
  • Myocytes, Cardiac (drug effects, pathology)
  • Rats
  • Receptors, Mineralocorticoid (genetics, physiology)
  • Spironolactone (pharmacology)
  • Up-Regulation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: